SHANGHAI INSTITUTE OF MATERIA MEDICA; CHINESE ACADEMY OF SCIENCES
发明人:
Yong GAN,Quanlei ZHU,Shiyan GUO,Chunliu ZHU
申请号：
US16469458
公开号：
US20200108008A1
申请日:
2017.12.15
申请国别(地区):
US
年份:
2020
代理人:
摘要：
An olaparib oral sustained and controlled release pharmaceutical composition contains an olaparib in an improved dissolution form and a release rate adjusting matrix polymer. The pharmaceutical composition has controllable in-vivo absorption behavior, plasma concentration and PARP enzyme inhibition level, and improved drug load and/or oral absorption and/or bioavailability and/or plasma concentration control and/or enzyme inhibition level control of olaparib, and can be used as the only preparation or in combination with other therapies to treat a cancer.
